Drug-eluting stents (DES) reduce intimal hyperplasia and restenosis, but they also inhibit stent endothelization, making the vascular surface more thrombogenic. The present report describes two cases of in-stent restenosis after DES deployment at exactly the same sites where subacute stent thrombosis had occurred. Extremely careful follow-up is mandatory after the recognition of intraluminal thrombi inside DES because restenosis may occur at the same site of DES thrombosis
EARLY RESTENOSIS AFTER DRUG ELUTING STENT IMPLANTATION: A PUTATIVE ROLE FOR PLATELET ACTIVATION
USSIA G;
2007-01-01
Abstract
Drug-eluting stents (DES) reduce intimal hyperplasia and restenosis, but they also inhibit stent endothelization, making the vascular surface more thrombogenic. The present report describes two cases of in-stent restenosis after DES deployment at exactly the same sites where subacute stent thrombosis had occurred. Extremely careful follow-up is mandatory after the recognition of intraluminal thrombi inside DES because restenosis may occur at the same site of DES thrombosisFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.